Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
135 hedge funds and large institutions have $1.15B invested in Sage Therapeutics in 2015 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 18 closing their positions.
129% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $4.7M
81% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 32
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
9% more funds holding
Funds holding: 124 → 135 (+11)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
40% less capital invested
Capital invested by funds: $1.93B → $1.15B (-$774M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$52.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$21.4M |
| 3 |
DM
Deerfield Management
New York
|
+$21.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$144M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$50.9M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$6.95M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.84M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$3.45M |
SAGE Hedge Fund Activity: Q3 2015 in Review
135 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2015, worth a combined $1.15B — down 40% from $1.93B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SAGE positions and 18 closed out — a net gain of 12 holders — while 58 added to existing stakes and 32 trimmed.
The largest buyer was Redmile Group, adding an estimated $52.5M. The largest seller was Third Rock Ventures, cutting an estimated $144M.
- 135 institutional investors held Sage Therapeutics (SAGE) as of Q3 2015, up from 124 in Q2 2015.
- Funds reported $1.15B of Sage Therapeutics stock for Q3 2015, down 40% quarter-over-quarter.
- 30 funds opened new Sage Therapeutics positions in Q3 2015 and 18 closed out, a net change of +12 holders.
- The largest Sage Therapeutics buyer in Q3 2015 was Redmile Group, an estimated $52.5M added.
- The largest Sage Therapeutics seller in Q3 2015 was Third Rock Ventures, an estimated $144M sold.
Based on aggregated 13F filings for Q3 2015.